Jan Beyer-Westendorf

No ORCID on file · 3 papers in corpus
rct 2021
Research and practice in thrombosis and haemostasis ·doi:10.1002/rth2.12474

BACKGROUND: Rivaroxaban may induce heavy menstrual bleeding. It is unknown if this effect is dose related or if rivaroxaban is associated with more menstrual bleeding than aspirin. OBJECTIVES: To demonstrate and compare menstrual patterns …

review 2021
Research and practice in thrombosis and haemostasis ·doi:10.1002/rth2.12512

Direct oral anticoagulants (DOACs) are replacing warfarin and other vitamin K antagonists for a wide range of indications. Advantages of DOAC therapy are fewer food and drug interactions and fixed dosing without routine laboratory monitorin…

observational 2016
Blood ·doi:10.1182/blood-2015-08-665927

Women receiving vitamin K antagonists (VKAs) require adequate contraception because of the potential for fetal complications. It is unknown whether the use of hormonal therapy, especially those containing estrogens, is associated with recur…